CN113058511B - Preparation method of oligonucleotide carrier microsphere - Google Patents
Preparation method of oligonucleotide carrier microsphere Download PDFInfo
- Publication number
- CN113058511B CN113058511B CN202110445594.7A CN202110445594A CN113058511B CN 113058511 B CN113058511 B CN 113058511B CN 202110445594 A CN202110445594 A CN 202110445594A CN 113058511 B CN113058511 B CN 113058511B
- Authority
- CN
- China
- Prior art keywords
- oligo
- polyethylene glycol
- pegda
- microspheres
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 20
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 39
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 15
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 12
- 238000004132 cross linking Methods 0.000 claims abstract description 3
- 125000004386 diacrylate group Chemical group 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 49
- 229920001002 functional polymer Polymers 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 8
- 239000000178 monomer Substances 0.000 claims description 8
- 239000000499 gel Substances 0.000 claims description 6
- 229920002674 hyaluronan Polymers 0.000 claims description 6
- 229960003160 hyaluronic acid Drugs 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 238000006845 Michael addition reaction Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 claims description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000004945 emulsification Methods 0.000 claims description 2
- 239000003999 initiator Substances 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 229920001427 mPEG Polymers 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- VLCAYQIMSMPEBW-UHFFFAOYSA-N methyl 3-hydroxy-2-methylidenebutanoate Chemical compound COC(=O)C(=C)C(C)O VLCAYQIMSMPEBW-UHFFFAOYSA-N 0.000 claims description 2
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 claims description 2
- 239000012266 salt solution Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 238000010557 suspension polymerization reaction Methods 0.000 claims description 2
- 238000012719 thermal polymerization Methods 0.000 claims description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- 229930024421 Adenine Natural products 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- 229960000643 adenine Drugs 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 239000000203 mixture Substances 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 238000011068 loading method Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- HHBBIOLEJRWIGU-UHFFFAOYSA-N 4-ethoxy-1,1,1,2,2,3,3,4,5,6,6,6-dodecafluoro-5-(trifluoromethyl)hexane Chemical compound CCOC(F)(C(F)(C(F)(F)F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F HHBBIOLEJRWIGU-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 239000007987 MES buffer Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000385 dialysis solution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- PZBFGYYEXUXCOF-UHFFFAOYSA-O tris(2-carboxyethyl)phosphanium Chemical compound OC(=O)CC[PH+](CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-O 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000012993 chemical processing Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000003203 nucleic acid sequencing method Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/14—Polymerisation; cross-linking
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
The invention discloses a preparation method of oligonucleotide (Oligo) carrier microspheres, which is characterized in that Oligo @ HB-PEGDA and molecules capable of reacting with HB-PEGDA (hyperbranched polyethylene glycol diacrylate) are mixed to prepare water-in-oil droplets, and the gel microspheres are formed by polymerization and crosslinking by taking the water-in-oil droplets as templates. The Oligo carrier microspheres prepared by the method have good monodispersity and controllable Oligo load amount, and can be widely applied to the fields of single cell analysis, in-vitro diagnosis and the like.
Description
Technical Field
The invention relates to biochemical analysis materials, in particular to a preparation method of oligonucleotide (Oligo) carrier microspheres.
Background
The bioactive supported Microsphere (Microsphere) is spherical particle with particle diameter of 50 nm-2 mm and has reactive group such as-NH2-COOH, -SH, etc. The microspheres have small size, so that the microspheres have obvious surface effects such as good affinity and biocompatibility of materials, easy absorption and migration in organisms and the like, and are widely applied to the fields of cytology, immunology, microbiology, molecular biology, clinical diagnosis and treatment, high-throughput gene detection and the like.
Nucleic acid hybridization using nucleic acids immobilized on a solid phase carrier as probes is of great importance in nucleic acid technology. The principle is that the immobilized single-stranded nucleic acid forms a double-helix structure when cooled in solution with a polynucleotide fragment having a complementary base sequence, thereby achieving the purpose of detection and sequence analysis of specific DNA. Yao Nuo and so on directionally link the 5 'end of oligonucleotide or directly link the 5' end of single-stranded DNA to the surface with methylamino (-CH)2NH2) And preparing a long-chain DNA probe on the PS microspheres with the functional groups. Such probes still have a relatively high coupling efficiency at higher temperatures. Therefore, the functionalized polymer microsphere is an ideal nucleic acid hybridization fixed carrier.
When the microspheres are used in a nucleic acid sequencing method, a nucleic acid sample with sequencing is modified by various biochemical methods and then is quickly and efficiently combined with corresponding reactive groups of the microspheres to realize loading; nucleic acid-loaded microspheres are introduced into the channels of the flow cell and into the corresponding reaction micro-tunnels, and incubated for a fixed time to generate all downstream chemical processing steps that are consistently capable of supporting amplification and sequencing. Compared with other types of nucleic acid loading methods, such as chip coating loading coating, the nucleic acid loading microspheres have the advantages of better controllability, large nucleic acid loading capacity and the like.
Disclosure of Invention
The purpose of the invention is as follows: the invention provides a preparation method of oligonucleotide (Oligo) carrier microspheres, which can effectively immobilize oligonucleotides. The microsphere can effectively immobilize oligonucleotide (Oligo) molecules, has good monodispersity and large oligonucleotide immobilization amount, and is favorable for capturing single-cell mRNA. The vector microsphere has good unicity, simple preparation method and large oligonucleotide immobilization capacity, and is beneficial to the application of single cell gene sequencing and the like.
The technical scheme is as follows: the invention aims to provide a preparation method of oligonucleotide (Oligo) carrier microspheres, which comprises the steps of mixing and reacting Oligo @ HB-PEGDA and molecules capable of reacting with HB-PEGDA to prepare water-in-oil droplets, and forming gel microspheres by polymerization and crosslinking by using the water-in-oil droplets as templates.
The preparation method comprises the following steps of (1) carrying out Michael addition reaction on the chemically modified Oligo fragment and hyperbranched PEGDA to prepare and obtain the difunctional HB-PEGDA; (2) taking the dual-functionalized HB-PEGDA as a basic unit, adding molecules capable of further reacting with the HB-PEGDA, and mixing to prepare a water-in-oil liquid drop; (3) and (3) initiating molecules in the liquid drop to polymerize under a proper condition to obtain gel microspheres, and washing out the gel microspheres to obtain the Oligo carrier microspheres.
In the preparation method, the chemically modified Oligo fragment in the step (1) is a thiol (-SH) group, an amino (-NH) group2) A modified Oligo fragment.
In the preparation method, the molecules capable of further reacting with HB-PEGDA in the step (2) are polyvinyl polyethylene glycol, sulfhydrylated functional polymers, double-bond functional polymers, amino functional polymers, polymeric monomers and the like.
In the preparation method, the polyvinyl polyethylene glycol can be multi-arm polyethylene glycol, tree-shaped polyethylene glycol and hyperbranched polyethylene glycol. The multi-Arm polyethylene glycol is respectively two-Arm polyethylene glycol ((Propargyl-PEG)2-Allyl), three-Arm polyethylene glycol (3Arm (PEG-Allyl3), four-Arm polyethylene glycol (4Arm (PEG-Allyl)4), six-Arm polyethylene glycol (6Arm-PEG-DA)), eight-Arm polyethylene glycol maleimide (8Arm-PEG-MAL), tree-shaped polyethylene glycol ((mPEG)4- (PEG)2-MAL), hyperbranched polyethylene glycol (hyperbranched polyethylene glycol diacrylate (HB-PEGDA)).
In the preparation method, the thiolated functional polymer can be thiolated hyaluronic acid and thiolated sodium alginate; the double-bond functional polymer can be double-bond gelatin, double-bond polyethylene glycol and the like.
The preparation method is characterized in that the polymerization monomer is one or more of acrylamide, dimethylacrylamide, isopropylacrylamide, hydroxyethyl methyl acrylate or polyethylene glycol acrylate.
In the preparation method, the water-in-oil droplet prepared in the step (2) is prepared by suspension polymerization, membrane emulsification and droplet microfluidics; the size range of the liquid drops is 1-1000 mu m.
The above production method is characterized in that the polymerization of the molecules inside the droplets is initiated under the appropriate conditions in the step (3) in such a manner that the molecules are mercapto (-SH), amino (-NH)2) The compound is subjected to Michael addition with the difunctional HB-PEGDA, and can also be prepared by using one or more of 2959, KPS or APS as a photoinitiator or a thermal initiator and then performing thermal polymerization or photoinitiated polymerization.
In the preparation method, in the step (3), the micron-sized hydrogel-in-oil microspheres are demulsified by adopting a sodium dodecyl sulfate solution, an alcohol, a salt solution or an ultrasonic method and then washed to obtain Oligo carrier microspheres.
Has the advantages that: compared with the prior art, the invention has the following remarkable effects: (1) the operation is simple, and the direct polymerization of the functional polymer microspheres is realized; (2) good controllability including regulation of microsphere reactive groups, regulation of microsphere size and regulation of the amount of the microspheres loaded with Oligo; (3) the maximum Oligo fragment loading capacity of the microspheres is large, single-cell gene sequencing is facilitated, the preparation method is simple, and the cost is low.
Drawings
FIG. 1 is a reaction scheme for the synthesis of HB-PEGDA;
FIG. 2 is a nuclear magnetic resonance hydrogen spectrum of a synthesized chemopolymer (HB-PEGDA);
FIG. 3 is a schematic diagram of a monodisperse Oligo carrier microsphere prepared by microfluidic technology.
Detailed Description
Example 1
(1) Synthesis of hyperbranched polyethylene glycol (HB-PEGDA) macromolecule: 11.5g of PEGDA monomer (average Mn. 575 g. mol.) was added-1) The resulting mixture was put into a flask, 50mL of butanone was added thereto, and the mixture was stirred until it was completely dissolved, thereby obtaining a monomer concentration of 0.4 mol. L-1The solution of (1). 0.1839g of Azobisisobutyronitrile (AIBN) and 0.2372g of tetraethylthiuram Disulfide (DS) were then added to the flask, the flask was sealed with a brine stopper and a sealing film was wound, and argon gas was bubbled through the mixture for 1 h. After preheating the oil bath to 70 ℃, the argon-filled mixture was placed at 70 ℃ for polymerization and the rotation speed was set at 300 rpm. After 6h of reaction, the reaction was stopped, air was bubbled through and the mixture was cooled to room temperature. The polymer was purified by precipitation three times with hexane/ether solution (1: 2v/v) (precooled in the refrigerator for 6h), the product was dried under reduced pressure and then dried in a vacuum oven for 48h to remove residual solvent to give the desired product.
(2) Preparation of thiolated hyaluronic acid: HA (100mg, 0.25mmol) was dissolved in 10ml MES buffer (pH 4.75, 0.1M), DTP (119mg, 0.5mmol) was added and dissolved with stirring; EDCI (96mg, 0.5mmol) was added, the pH of the solution was maintained at 4.75, and the reaction was carried out for 5 h; adding 1.0mol/L NaOH to adjust the pH of the reaction mixture to 7.0; DTT (501mg, 3.25mmol) was added and the pH of the solution was adjusted to 8.5 by the addition of 1.0 mol/LNaOH; the mixture was stirred for 24 hours and the pH of the reaction mixture was adjusted to 3.5 by addition of 1.0mol/L HCl; the acidified solution was transferred to a dialysis belt (molecular weight cut-off of 10kDa) and dialyzed against dilute HCl containing 0.1M NaCl for 24h (pH 3.5) followed by dialysis against deionized water for 24h (pH 3.5) with dialysis fluid changed every 12 h. The acidified solution was lyophilized for 72h to obtain solid HA-SH.
(3) Functional modification of HB-PEGDA with Oligo primers (Oligo @ HB-PEGDA): 75mg of HB-PEGDA was dissolved in 250. mu.L of PBS solution to give a 30% HB-PEGDA solution. 250 μ L of an oligo solution of a certain concentration was mixed with the prepared HB-PEGDA solution, and then the pH thereof was adjusted to weak alkalinity with a 1M NaOH solution, and the solution was incubated at 37 ℃ for 12 hours with shaking at 600 rpm. And (3) adjusting the pH value of the solution to be alkalescent by using a 1M NaOH solution to obtain an Oligo @ HB-PEGDA macromolecular solution with the Oligo fragments and double bonds being double-functionalized.
(4) Preparation of Oligo vector microspheres: HFE-7500 at 0.1% (v/v) surfactant was formulated as continuous phase P3, and 3mL of the solution was loaded into syringe A. Syringe B was filled with Oligo @ HB-PEGDA polymer solution. 2.9mg of tris (2-carboxyethyl) phosphonium (TECP) was weighed out and dissolved in 1mL of PBS to prepare a 10mM (TECP) solution. 20mg of thiolated hyaluronic acid (SH-HA) was weighed out and dissolved in 1mL of a (TECP) solution, and then the pH was adjusted to weak alkalinity with 1M NaOH solution, which was filled into two syringes C1 and C2. Each syringe contained 500 μ LSH-HA solution. Syringes of a, B, C1 and C2 were connected to the respective inlets of the microfluidic chip by PTFE tubes. Each syringe was housed in a syringe pump. For syringe A, the flow rate was set to 1000. mu.L/h, for syringe B of HBPEG solution, the flow rate was set to 100. mu.L/h, and for each of syringes C1 and C2 of oligo dT SH-HA solution, the droplet generation process was as shown in FIG. 3. And connecting the PTFE tube with an outlet of the microfluidic chip, collecting the micro-droplets by using a centrifugal tube after the droplet generation process is stable, standing for 2 hours after the collection is finished, removing the oil phase after the micro-droplets are solidified, and adding pure HFE-7500 to wash for multiple times to remove the surfactant. HFE-7500 was removed and the resulting oligo carrier hydrogel microspheres were dispersed in PBS.
Example 2
(1) Synthesis of hyperbranched polyethylene glycol (HB-PEGDA) macromolecule: 11.5g of PEGDA monomer (average Mn. 575 g. mol.) was added-1) The resulting mixture was put into a flask, 50mL of butanone was added thereto, and the mixture was stirred until it was completely dissolved, thereby obtaining a monomer concentration of 0.4 mol. L-1The solution of (1). 0.1839g of Azobisisobutyronitrile (AIBN) and 0.2372g of tetraethylthiuram Disulfide (DS) were then added to the flask, the flask was sealed with a stopper of saline and a sealing film was wound and argon was bubbled through the mixture for 1 h. After preheating the oil bath to 70 ℃, the argon-filled mixture was placed at 70 ℃ for polymerization and the rotation speed was set at 300 rpm. After 6h of reaction the reaction is stoppedAir was then introduced and the mixture was cooled to room temperature. The polymer was purified by precipitation three times with hexane/ether solution (1: 2v/v) (precooled in the refrigerator for 6h), the product was dried under reduced pressure and then dried in a vacuum oven for 48h to remove residual solvent to give the desired product.
(2) Preparation of thiolated hyaluronic acid: HA (100mg, 0.25mmol) was dissolved in 10ml MES buffer (pH 4.75, 0.1M), DTP (119mg, 0.5mmol) was added and dissolved with stirring; EDCI (96mg, 0.5mmol) was added, the pH of the solution was maintained at 4.75, and the reaction was carried out for 5 h; adding 1.0mol/L NaOH to adjust the pH of the reaction mixture to 7.0; DTT (501mg, 3.25mmol) was added and the pH of the solution was adjusted to 8.5 by the addition of 1.0 mol/LNaOH; the mixture was stirred for 24 hours and the pH of the reaction mixture was adjusted to 3.5 by addition of 1.0mol/L HCl; the acidified solution was transferred to a dialysis belt (molecular weight cut-off of 10kDa) and dialyzed against dilute HCl containing 0.1M NaCl for 24h (pH 3.5) followed by dialysis against deionized water for 24h (pH 3.5) with dialysis fluid changed every 12 h. The acidified solution was lyophilized for 72h to obtain solid HA-SH.
(3) Functional modification of HB-PEGDA with Oligo primers (Oligo @ HB-PEGDA): 75mg of HB-PEGDA was dissolved in 250. mu.L of PBS solution to give a 30% HB-PEGDA solution. 250 μ L of an oligo solution of a certain concentration was mixed with the prepared HB-PEGDA solution, and then the pH thereof was adjusted to weak alkalinity with a 1M NaOH solution, and the solution was incubated at 37 ℃ for 12 hours with shaking at 600 rpm. And (3) adjusting the pH value of the solution to be alkalescent by using a 1M NaOH solution to obtain an Oligo @ HB-PEGDA macromolecular solution with the Oligo fragments and double bonds being double-functionalized.
(4) Preparation of Oligo vector microspheres: methyl silicone oil with 5% (v/v) surfactant (749) was formulated as continuous phase P3, and 3mL of the solution was loaded into syringe a. Syringe B was filled with Oligo @ HB-PEGDA polymer solution. 2.9mg of tris (2-carboxyethyl) phosphonium (TECP) was weighed out and dissolved in 1mL of PBS to prepare a 10mM (TECP) solution. 20mg of thiolated hyaluronic acid (SH-HA) was weighed out and dissolved in 1mL of a (TECP) solution, and then the pH was adjusted to weak alkalinity with 1M NaOH solution, which was filled into two syringes C1 and C2. Each syringe contained 500. mu.L of SH-HA solution. Syringes of a, B, C1 and C2 were connected to the respective inlets of the microfluidic chip by PTFE tubes. Each syringe was housed in a syringe pump. For syringe A, the flow rate was set to 1000. mu.L/h, for syringe B of HBPEG solution, the flow rate was set to 100. mu.L/h, and for each of syringes C1 and C2 of oligo dT SH-HA solution, the droplet generation process was as shown in FIG. 3. And connecting the PTFE tube with an outlet of the microfluidic chip, collecting the micro-droplets by using a centrifugal tube after the droplet generation process is stable, standing for 2 hours after the collection is finished, removing the oil phase after the micro-droplets are solidified, and adding n-hexane for washing for multiple times to remove the surfactant. The n-hexane was removed and the oligo carrier microspheres were dispersed in PBS.
Claims (9)
1. A preparation method of oligonucleotide (Oligo) carrier microspheres is characterized in that: mixing Oligo @ HB-PEGDA and molecules capable of reacting with HB-PEGDA to prepare a water-in-oil droplet, and using the water-in-oil droplet as a template to form gel microspheres through polymerization and crosslinking;
the preparation method comprises the following steps:
(1) carrying out Michael addition reaction on the chemically modified Oligo fragment and HB-PEGDA to prepare Oligo @ HB-PEGDA;
(2) taking Oligo @ HB-PEGDA as a basic unit, adding molecules which can further react with the HB-PEGDA, and mixing to prepare a water-in-oil droplet;
(3) and (3) initiating molecules inside the liquid drops to polymerize under a proper condition to obtain gel microspheres, and purifying the gel microspheres to obtain the Oligo carrier microspheres.
2. The method of claim 1, wherein the oligonucleotide (Oligo) vector microsphere is prepared by: the Oligo fragment chemically modified in the step (1) is a thiol (-SH) group or an amino (-NH) group2) The modified Oligo fragment has a sequence of a macromolecular polymer consisting of deoxynucleotides, wherein bases comprise one or more of adenine (A), guanine (G), thymine (T) and cytosine (C), the bases are arranged in any sequence, and the number of the bases is 1-50.
3. The method of claim 1, wherein the oligonucleotide (Oligo) vector microsphere is prepared by: the molecules which can further react with HB-PEGDA in the step (2) are polyvinyl polyethylene glycol, sulfhydrylation functional polymers, double bond functional polymers, amino functional polymers, small molecular monomers and the like.
4. The method for preparing oligonucleotide (Oligo) vector microspheres according to claim 3, wherein: the polyvinyl polyethylene glycol can be multi-arm polyethylene glycol, tree polyethylene glycol and hyperbranched polyethylene glycol. The multi-Arm polyethylene glycol is respectively two-Arm polyethylene glycol ((Propargyl-PEG)2-Allyl), three-Arm polyethylene glycol (3Arm (PEG-Allyl3), four-Arm polyethylene glycol (4Arm (PEG-Allyl)4), six-Arm polyethylene glycol (6Arm-PEG-DA)), eight-Arm polyethylene glycol maleimide (8Arm-PEG-MAL), tree-shaped polyethylene glycol ((mPEG)4- (PEG)2-MAL), hyperbranched polyethylene glycol (hyperbranched polyethylene glycol diacrylate (HB-PEGDA)).
5. The method for preparing oligonucleotide (Oligo) vector microspheres according to claim 3, wherein: the sulfhydrylation functional polymer can be one or more of sulfhydrylation hyaluronic acid, sulfhydrylation sodium alginate, sulfhydrylation gelatin and the like; the double-bond functional polymer can be one or more of double-bond gelatin, double-bond polyethylene glycol and the like.
6. The method for preparing oligonucleotide (Oligo) vector microspheres according to claim 3, wherein: the polymerization monomer is one or more of acrylamide, dimethylacrylamide, isopropyl acrylamide, hydroxyethyl methyl acrylate or polyethylene glycol acrylate.
7. The method for preparing oligonucleotide (Oligo) carrier microspheres according to claim 1, wherein: the water-in-oil droplet prepared in the step (2) is prepared by suspension polymerization, membrane emulsification and droplet microfluidics; the size of the droplets is in the range of 1 μm to 1000. mu.m.
8. The method of claim 1, wherein the oligonucleotide (Oligo) vector microsphere is prepared by: the polymerization of the molecules in the liquid drops under the proper conditions in the step (3) can be initiated by sulfydryl (-SH) and amino (-NH)2) The compound is subjected to Michael addition with the difunctional HB-PEGDA, and can also be prepared by using one or more of 2959, KPS or APS as a photoinitiator or a thermal initiator and then performing thermal polymerization or photoinitiated polymerization.
9. The method of claim 1, wherein the oligonucleotide (Oligo) vector microsphere is prepared by: and (3) demulsifying the micron-sized hydrogel-in-oil microspheres by adopting a sodium dodecyl sulfate solution, an alcohol, a salt solution or an ultrasonic method, and then washing to obtain Oligo carrier microspheres.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110445594.7A CN113058511B (en) | 2021-04-23 | 2021-04-23 | Preparation method of oligonucleotide carrier microsphere |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110445594.7A CN113058511B (en) | 2021-04-23 | 2021-04-23 | Preparation method of oligonucleotide carrier microsphere |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113058511A CN113058511A (en) | 2021-07-02 |
CN113058511B true CN113058511B (en) | 2022-05-13 |
Family
ID=76567509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110445594.7A Active CN113058511B (en) | 2021-04-23 | 2021-04-23 | Preparation method of oligonucleotide carrier microsphere |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113058511B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112458075B (en) * | 2020-11-24 | 2023-07-25 | 南京工业大学 | Method for strengthening microbial catalytic process by using double cross-linked particle gel packed column |
CN113429523B (en) * | 2021-07-09 | 2023-05-09 | 西南石油大学 | Core-shell polymer microsphere and preparation method thereof |
CN113797904A (en) * | 2021-09-30 | 2021-12-17 | 苏州赛分科技股份有限公司 | Chromatographic medium for capturing mRNA and preparation method thereof |
CN114773608A (en) * | 2022-04-18 | 2022-07-22 | 南京工业大学 | Long-acting hyaluronic acid for treating osteoarthritis and preparation method thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112048033B (en) * | 2020-09-04 | 2021-10-29 | 湖南大学 | Hydrogel microcarrier and preparation method and application thereof |
-
2021
- 2021-04-23 CN CN202110445594.7A patent/CN113058511B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN113058511A (en) | 2021-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113058511B (en) | Preparation method of oligonucleotide carrier microsphere | |
CN105925572B (en) | DNA coding microsphere and synthetic method thereof | |
AU2019346419B2 (en) | Three-dimensional bioreactors | |
JP2020509746A (en) | Microgel particles and related compositions, systems, and methods for use in 3D printing and 3D cell culture media | |
CN101633712A (en) | Point-and-click temperature/pH-sensibility microgel | |
CN101235117A (en) | Copolymerization reaction method for styrene/maleic anhydride | |
CN109400888B (en) | Water-soluble star polymer based on beta-cyclodextrin as core and preparation method thereof | |
Lee et al. | The mechanism of core–shell inversion in two‐stage latexes | |
CN111195371A (en) | Micro-heterotype cell-carrying alginic acid gel and preparation method and application thereof | |
CN101381435B (en) | Preparation method of spherical polyelectrolyte brush and use thereof | |
CN104262554B (en) | Self-crosslinkable responsive to temperature type hybrid block copolymer and preparation method thereof | |
CN104744650A (en) | Preparation and application of hybrid copolymer containing POSS (polyhedral oligomeric silsesquioxane) base | |
CN104387712A (en) | Nano composite carrier with superparamagnetism and preparation method thereof | |
CN110585476B (en) | Preparation method of non-spherical hydrogel microparticle embolic agent | |
CN1278534A (en) | Polymer microball with fluorescent mark and its preparation | |
CN103130951A (en) | Method for preparing P(SMA-co-DM) in micro-reactor through free radical polymerization | |
CN103865012A (en) | Preparation of polymer-polypeptide bioconjugate with comb-shaped structure | |
CN107236078B (en) | Preparation method of flexible soft monomer colloid photonic crystal emulsion | |
CN111269368B (en) | Method for preparing surface microphase separation nanoparticles by RAFT polymerization induced self-assembly | |
CN103394305A (en) | pH-responsive star-shaped polymer emulsifier and preparation method thereof | |
CN115505160B (en) | Preparation method of hydrogel microsphere carrier, product obtained by preparation method and application of hydrogel microsphere carrier | |
CN109897179B (en) | Multi-arm polyethylene glycol-poly (L-glutamate) block copolymer, and preparation method and application thereof | |
CN115536790A (en) | Star polymer/metal nanoparticle compound with stimulus response function and continuous flow microreaction preparation method and application thereof | |
Huang et al. | Synthesis and DNA adsorption of poly (2-Vinyl-4, 6-Diamino-1, 3, 5-Triazine) coated polystyrene microspheres | |
Daniels et al. | Overview of Polymer Colloids: Preparation, Characterization, and Applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |